PEL

Piramal Enterprises Limited has informed the Exchange regarding a Press Release dated August 06, 2015 titled '' Piramal Enterprises Consolidated Results for the First Quarter ended 30 June 2015 "

Piramal Enterprises Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Jun-2015.

Piramal Enterprises Limited has informed the Exchange regarding Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, Company's Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

Piramal Enterprises Limited has informed the Exchange that the Trading Window for dealing in the securities of the Company is closed from July 30, 2015 to August 8, 2015 i.e. after 48 hours from the time the results are communicated to the Stock Exchanges on the date of the Meeting.

Piramal Enterprises Limited has informed the Exchange regarding extension of Closure of Trading Window.

Piramal Enterprises Limited has informed the Exchange regarding "Errata - Audited financial results for the year ended March 31, 2015.

Piramal Enterprises Limited had informed the Exchange that the Trading Window for dealing in the securities of the Company will remain closed from April 30, 2015 to May 8, 2015, in view of consideration of the Financial Results of the Company for the year ended March 31, 2015, by the Board at its Meeting held May 7, 2015. The Company has now informed that the Board Meeting was held May 7, 2015, it has been decided to hold another Board Meeting on May 29, 2015 to finish some of the unfinished agenda items that were listed in May 7, 2015 Board Meeting agenda. In view of this, it has been decided

Piramal Enterprises Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from July 30, 2015 to August 6, 2015 (both days inclusive) for the purpose of payment of Dividend and Annual General Meeting (AGM) of the Company to be held on August 6, 2015.

Piramal Enterprises Limited has informed the Exchange that the dividend on Equity Shares, if declared by the Members at the AGM of the Company, will be paid to the members between August 7, 2015 and August 11, 2015.

Piramal Enterprises Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 7, 2015, recommended dividend of Rs. 20 (Rupees Twenty only) per equity share of face value of Rs. 2/- (i.e. @ 1000%) for the financial year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting ('AGM') of the Company.

Piramal Enterprises Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2015.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated May 7, 2015 titled "Piramal Enterprises Consolidated Results for the Fourth Quarter and Full Year ended 31 March 2015 ".

Piramal Enterprises Limited has informed the Exchange that the Trading Window for dealing in the securities of the Company by its Directors /Officers / Designated Employees will remain closed from April 30, 2015 to May 08, 2015 in terms of clause 3.2.3 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 and clause V of Code for Prevention of Insider Trading in Securities of the Company.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated April 17, 2015, titled "Piramal Enterprises Limited agrees to acquire majority equity stake in Health SuperHiway Private Limited".

Ajay G Piramal has submitted to the Exchange vide letter dated April 01, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated April 01, 2015 titled "Piramal Enterprises announces sale of its Hyderabad based Clinical Research Division to Indoco Remedies".

The Sri Krishna Trust has submitted to the Exchange vide letter dated March 18, 2015 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

The Sri Krishna Trust has submitted to the Exchange, vide letter dated March 18, 2015 a copy of disclosure under Regulation 10(6) in respect of acquisition under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

The Exchange had sought clarification from Piramal Enterprises Limited with respect to a news item captioned "Piramal may buy Apollo's Health Super HiWay". The Company has clarified that "As part of its growth strategy, the Company continually looks at strategic initiatives including viable investment opportunities. All of these are channelled towards achieving operational excellence and growth. So far as the captioned news article is concerned, the Company's proposed investment in Health Super HiWay is subject to several pre-conditions, only upon fulfillment of which, the investment would be

The Exchange has sought clarification from Piramal Enterprises Limited with respect to recent news item captioned "Piramal May Buy Apollo's Health Super HiWay". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any informat

The Sri Krishna Trust has submitted to the Exchange, vide letter dated March 9, 2015 a copy of disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Spurt in Volume : Substantial increase in trading volumes have been observed in Piramal Enterprises Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Enterprises Limited has vide its letter inter-alia stated, "We would like to clarify that we are not aware of such information/announcement (including impending announcement)."

Piramal Enterprises Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated February 9, 2015 titled "Piramal Enterprises Consolidated Results for the Third Quarter and Nine Months ended 31 December 2014".

Piramal Enterprises Limited has informed the Exchange that the Trading Window for dealing in the securities of the Company by its Directors/Officers/Designated Employees of the Company is closed from Saturday, January 31, 2015 to Tuesday, February 10, 2015 in terms of clause 3.2.3 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 and clause V of Code for Prevention of Insider Trading in Securities of the Company.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated January 16, 2015 titled "Piramal Enterprises acquires Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc".

The Exchange had sought clarification from Piramal Enterprises Limited with respect to an announcement dated January 16, 2015, regarding a press release dated January 15, 2015 titled "Piramal Enterprises considers potential acquisition of Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc". The Company has clarified as follows: 1. Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof; Reply: As mentioned in the Press Release, no related party of Piramal Enterprises Limited (i

The Exchange has sought clarification from Piramal Enterprises Limited with respect to an announcement dated January 16, 2015, regarding a press release dated January 15, 2015 titled "Piramal Enterprises considers potential acquisition of Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc". On basis of above the Company is required to clarify following: 1. Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof; 2. Nature of consideration - whether cash consideration or share s

Piramal Enterprises Limited has informed the Exchange regarding a press release dated January 15, 2015 titled "Piramal Enterprises considers potential acquisition of Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc".

The Exchange had sought clarification from Piramal Enterprises Limited with respect to a recent news item captioned "Piramal's pharma arm to invest $40m in new tech". The Company has clarified that "As part of its strategy, the Company's Pharma Solutions division continually looks at viable investment opportunities for augmenting its existing capacity and adding new capabilities, including by way of adding new equipments and incorporating new technologies. All of these are channelled towards achieving operational excellence and growth. Recently, the Company has completed a series of these ini

The Exchange has sought clarification from Piramal Enterprises Limited with respect to recent news item captioned "Piramal's pharma arm to invest $40 m in new tech". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any inf

The Exchange has sought clarification from Piramal Enterprises Limited with respect to a news item captioned "Piramal Enterprises have acquired 2 BOT Infra Projects from Supreme Infra worth Rs. 700 crores". The Company has clarified that "The Company from time to time explores various investment opportunities as part of its structured investment business, in the normal course of its business. This evaluation of opportunities includes various criteria, including technical, financial, taxation, commercial, regulatory and legal. Once these criteria are met, it is followed by internal approvals at

Piramal Enterprises Limited has informed the Exchange that Mr. Vijay Shah, Executive Director of the Company whose current tenure was expiring on December 31, 2014 has been re-appointed as the Whole Time Director of the Company, designated as Executive Director, for a further period of 3 years with effect from January 1, 2015. The above appointment is subject to the approval of the shareholders and applicable regulatory approvals.

Piramal Enterprises Limited has informed the Exchange that Mr. Ajay G. Piramal, Chairman of Piramal Enterprises Limited, has been appointed as the Non-Executive Chairman of Shriram Capital Limited at its Board Meeting held on November 15, 2014.

Piramal Enterprises Limited has submitted to the Exchange vide letter dated November 14, 2014 a copy of disclosure under Regulation 13(4) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Piramal Enterprises Limited has submitted to the Exchange vide letter dated October 27, 2014 a copy of disclosure under Regulation 13(4) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Piramal Enterprises Limited has submitted to the Exchange a copy of revised statement showing the consolidated segment results for the quarter and half year ended ended September 30, 2014.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated October 21, 2014 titled "Piramal Enterprises announces Q2 & H1FY2015 results".

Piramal Enterprises Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Piramal Enterprises Limited has informed the Exchange with reference to news item appearing in the newspaper titled "Piramal Leads Race for 3 Ramky Highway Projects". "In this regard, we would like to state that the Company from time to time explores various investment opportunities as part of its structured investment business, in the normal course of its business. Not all of these result in definitive actions, and may or may not necessarily result into transactions. Hence, any comment by us on speculative reports, without any disclosable event having taken place, could potentially impact

The Exchange had sought clarification from Piramal Enterprises Limited with respect to a news item captioned "DiaSys to buy Piramal's diagnostic business". The Company has clarified that "The Company has signed an agreement for sale of its Lab Diagnostics & Point of Care Business to Diasys Diagnostics India Private Limited, for a consideration of Rs. 13.00 crores. In addition, the Company would be transferring related technology for a consideration of Rs. 0.30 crores. It is relevant to note here that this business, comprising buying and selling of diagnostic equipments, serving large pathologi

The Exchange sought clarification from Piramal Enterprises Limited with respect to news item captioned "Piramal to exit drug discovery business". The Company has clarified that "The Company has only decided to scale back its investments in NCE R&D activity in Mumbai. We would like to clarify that New Chemical Entity Research (NCE R&D) is only a part of the Company s R&D Activity, which also encompasses research in Radiopharmaceuticals, Anesthesia and Pharma Solutions, which have a relatively higher likelihood of success, as against the NCE R&D where the pipeline of projects are at early st

Piramal Enterprises Limited has informed the Exchange regarding a press release dated August 27, 2014, titled, "Piramal Enterprises enters into a Joint Venture with Navin Fluorine for specialty Fluorochemicals with applications in healthcare".

Piramal Enterprises Limited has informed the Exchange regarding a press release dated August 06, 2014 with respect to the Unaudited Financial Results (consolidated and standalone) of the Company for the quarter ended June 30, 2014.

Piramal Enterprises Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated July 30, 2014, titled, "APG and Piramal Enterprises Limited Announce Strategic Investment Alliance".

Piramal Enterprises Limited has informed the Exchange regarding the details of Voting results at the Annual General Meeting (AGM) of the Company held on July 25, 2014, under Clause 35A.

Piramal Enterprises Limited has submitted to the Exchange vide letter dated June 20, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Piramal Enterprises Limited has submitted to the Exchange vide letter dated June 20, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Piramal Enterprises Limited has submitted to the Exchange vide letter dated June 20, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.